More Than Just Humira: US Biosimilars Enjoy An Eventful 2023
Adalimumab Competition Hits, Firms Settle On Stelara And New Biosimilars Approved
The launch of competition to Humira was the main event for US biosimilars this year – but a number of other key developments also took place in 2023, including settlements on Stelara that set up a series of launches in 2025, as well as first approvals for ustekinumab, natalizumab and tocilizumab biosimilars.
